Balthaser Kevin 4

What Happened
Kevin Balthaser, Chief Financial Officer of Aclaris Therapeutics (ACRS), had 2,375 restricted stock units (RSUs vest and convert) into common shares on March 1, 2026. Of those shares, 677 were withheld by the issuer to satisfy the reporting person’s tax withholding obligation, resulting in proceeds of about $1,943 (677 shares × $2.87). The filing shows the RSU conversion as an exercise/conversion of a derivative (code M) and the share withholding for taxes as a payment of tax liability (code F).

Key Details

• Transaction date: 2026-03-01; Form 4 filed: 2026-03-03 (filed two days after the transaction).
• Acquired: 2,375 shares from conversion/vesting of RSUs (code M).
• Withheld/disposed for taxes: 677 shares at $2.87 per share, total ~$1,943 (code F).
• The filing’s derivative entry also lists a 2,375-share disposition at $0 — consistent with conversion/settlement mechanics of RSUs (shares issued then partially withheld).
• Footnotes: F1—each RSU equals one contingent share; F2—issuer withheld shares to satisfy tax obligations; F3—these RSUs vest in four equal annual installments beginning March 1, 2023, subject to continued service.
• Shares owned after the transaction are not disclosed in the provided data.

Context: This was a routine vesting/settlement of RSUs, not an open-market purchase or sale intended as an investment signal. Withholding of shares to cover taxes is common and does not necessarily indicate a change in the insider’s view of the company. Transaction codes: M = exercise/conversion of derivative (RSU vesting), F = payment of tax liability via share withholding.